Cargando…
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines
BACKGROUND: There is no effective treatment strategy for advanced castration-resistant prostate cancer. Although Docetaxel (Taxotere(®)) represents the most active chemotherapeutic agent it only gives a modest survival advantage with most patients eventually progressing because of inherent or acquir...
Autores principales: | O'Neill, Amanda J, Prencipe, Maria, Dowling, Catherine, Fan, Yue, Mulrane, Laoighse, Gallagher, William M, O'Connor, Darran, O'Connor, Robert, Devery, Aoife, Corcoran, Claire, Rani, Sweta, O'Driscoll, Lorraine, Fitzpatrick, John M, Watson, R William G |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3203088/ https://www.ncbi.nlm.nih.gov/pubmed/21982118 http://dx.doi.org/10.1186/1476-4598-10-126 |
Ejemplares similares
-
A novel mechanism of regulation of the anti-metastatic miR-31 by EMSY in breast cancer
por: Mulrane, Laoighse, et al.
Publicado: (2014) -
Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes
por: Corcoran, Claire, et al.
Publicado: (2012) -
The effect of ‘paying for performance’ on the management of type 2 diabetes mellitus: a cross-sectional observational study
por: O'Connor, Raymond, et al.
Publicado: (2020) -
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
por: Corcoran, Claire, et al.
Publicado: (2014) -
miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity
por: O'Brien, Keith, et al.
Publicado: (2015)